Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung.

@article{Campbell2016PulmonaryPO,
  title={Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung.},
  author={Jamie L Campbell and Josquin Nys and Laura Eghobamien and E Suzanne Cohen and Matthew J. Robinson and Matthew A Sleeman},
  journal={mAbs},
  year={2016},
  volume={8 7},
  pages={1398-1406}
}
Pulmonary alveolar proteinosis is associated with impaired alveolar macrophage differentiation due to genetic defects in the granulocyte macrophage colony-stimulating factor (GM-CSF) axis or autoantibody blockade of GM-CSF. The anti-GM-CSFRα antibody mavrilimumab has shown clinical benefit in patients with rheumatoid arthritis, but with no accompanying pulmonary pathology observed to date. We aimed to model systemic versus pulmonary pharmacodynamics of an anti-GM-CSFRα antibody to understand… CONTINUE READING